<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814942</url>
  </required_header>
  <id_info>
    <org_study_id>2016/00608</org_study_id>
    <nct_id>NCT02814942</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Asians With CRT for Heart Failure</brief_title>
  <acronym>PEACH</acronym>
  <official_title>Prospective Evaluation of Asians With CRT for Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Heart Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Heart Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim:To determine the baseline characteristics of heart failure patients in Singapore&#xD;
      undergoing cardiac resynchronization therapy (CRT); the long term outcome and predictors of&#xD;
      response to CRT.&#xD;
&#xD;
      Methodology:Among patients undergoing CRT for severe heart failure according to indications&#xD;
      stipulated in international Cardiology guidelines, baseline demographic data is collected.&#xD;
      Age, gender, NYHA functional class, co-morbidities, QRS width on ECG, presence of left bundle&#xD;
      branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection&#xD;
      fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are&#xD;
      collected. In addition, during the CRT implant procedure, blood is drawn from the vascular&#xD;
      access and analysed for NT-pro BNP levels and other biomarkers of heart failure.&#xD;
&#xD;
      The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and&#xD;
      12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV&#xD;
      (left ventricular end-systolic volume index to body surface area) of &gt;/= 15% and/or an&#xD;
      increase in the LVEF of &gt;/= 10%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among patients undergoing CRT for severe heart failure according to indications stipulated in&#xD;
      international Cardiology guidelines, baseline demographic data is collected. Age, gender,&#xD;
      NYHA functional class, comorbidities, QRS width on ECG, presence of left bundle branch block&#xD;
      pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on&#xD;
      echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition,&#xD;
      during the CRT implant procedure, blood is drawn from the vascular access and analysed for&#xD;
      NT-pro BNP levels and other biomarkers of heart failure. The echocardiographic and ECG&#xD;
      parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT&#xD;
      implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular&#xD;
      end-systolic volume index to body surface area) of &gt;/= 15% and/or an increase in the LVEF of&#xD;
      &gt;/= 10%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Years</target_duration>
  <primary_outcome>
    <measure>Echocardiographic response to CRT</measure>
    <time_frame>6 months</time_frame>
    <description>A subject is considered an echocardiographic responder to CRT if there is:&#xD;
reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of &gt;/= 15% OR&#xD;
an increase in the LVEF of &gt;/= 10% during follow-up echocardiography at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrine response to CRT</measure>
    <time_frame>6 months</time_frame>
    <description>A subject is considered to have a neuro-endocrine response to CRT if BNP levels at 6 months post CRT implant has fallen more than 30% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response to CRT</measure>
    <time_frame>6 months</time_frame>
    <description>A subject is considered a positive clinical responder to CRT if:&#xD;
NYHA class has improved by at least 1 class OR&#xD;
6 minutes walking test has increased by at least 10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization For Cardiovascular events</measure>
    <time_frame>8 years</time_frame>
    <description>Hospitalisation for acute coronary syndrome, heart failure, arrhythmias, ICD shocks or any unplanned admissions for any cardiac interventions or surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>8 years</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiac Resynchronisation Therapy</condition>
  <arm_group>
    <arm_group_label>Heart Failure receiving CRT</arm_group_label>
    <description>Heart failure patients with QRS &gt; 120ms receiving CRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy</intervention_name>
    <description>Cardiac resynchronization therapy with or without ICD</description>
    <arm_group_label>Heart Failure receiving CRT</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum saved for biomarking&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Singaporean patients with broad QRS complexes, EF &lt;40%, heart failure, requiring CRT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Broad QRS (&gt;120 ms)&#xD;
&#xD;
          -  EF &lt; 40%&#xD;
&#xD;
          -  Symptomatic heart failure&#xD;
&#xD;
          -  Not on optimal medical therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
&#xD;
          -  Infection&#xD;
&#xD;
          -  Unable to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Swee Chong Seow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pipin Kojodjojo, MD PHD</last_name>
    <phone>67795555</phone>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pipin Kojodjojo, MD PHD</last_name>
      <phone>67795555</phone>
    </contact>
    <investigator>
      <last_name>Swee Chong Seow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University Heart Centre, Singapore</investigator_affiliation>
    <investigator_full_name>Pipin Kojodjojo</investigator_full_name>
    <investigator_title>Consultant Cardiac Electrophysiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

